Abstract:
Background: Male circumcision(MC) can reduce HIV acquisition. However, a better understanding of the indirect protective effect of MC on sexually transmitted infections (STIs) is required.
Objective: To assess the incremental benefits conferred by MC on HIV infection at the individual-level in circumcision trials (no herd immunity effect) and at the populationlevel (with herd immunity effect) due to its protective effect against other STIs.
Methods: A dynamical stochastic model of HIV and STI infections in a Kenyan
population was used to simulate the impact of circumcision offered to a minority of trials participants or to a large fraction of men in order to study the protective role of MC on HIV infection at the individual-level and at the population-level, respectively.
Results:
Less than 20% of the HIV infections prevented in the circumcised arm of the circumcision trials (individual-level) could be attributable to MC efficacy against STIs rather than MC efficacy against HIV. At the population-level, MC can significantly reduce HIV prevalence especially among males and among females in the longer term.
However, even at the population-level, the long-term incremental impact of MC on HIV due to the protection against STI is modest (even if MC efficacy against the STI and STI prevalence was high). The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in STI and any other BMJPGL products and sub-licences such use and exploit all subsidiary rights, as set out in our licence http://sti.bmjjournals.com/ifora/licence.pdf)". If your manuscript does not contain this statement, you will be contacted by the Editorial staff to ensure that it is added.
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Introduction
There is compelling evidence that male circumcision(MC) reduces susceptibility to HIV infection. Early evidence was based on ecological and observational studies (1) (2) (3) (4) (5) (6) (7) (8) (9) . Results from a meta-analysis of observational studies showed a 50% and 70% reduction in HIV risk amongst circumcised men from the general population and higher-risk groups, respectively (6) . The most compelling evidence comes from three recent unblinded randomised control trials(RCT) conducted among adult men in Kenya, Uganda and South Africa(10-12) which suggested a 50% to 60% reduction in HIV risk among circumcised men across the three trials (Table 1) .
Given the overwhelming evidence and the limited preventive options available, WHO/UNAIDS have published recommendations for countries to consider scaling up access to MC in seronegative men, in areas of high HIV prevalence where MC is rare (13) . However, a number of important issues such as the safety, cost, feasibility, acceptability, ethics, and potential increase in risky behaviour following circumcision should be considered ideally before the large scale implementation of MC (13) . A better understanding of the potential population-level impact of MC is needed in order to identify who should be circumcised. Further research is needed to guide programme implementation and to better understand additional benefits or risks of MC, including the protective effects of MC on other sexually transmitted infections(STIs) (13) . Without conducting community based randomised trials, the impact of circumcision at the population-level can be addressed with mathematical modelling if we have a clear understanding of the protective biological mechanisms of MC at the individual-level. To achieve this, it is useful to clearly understand the results of the circumcision trials and to make a distinction between efficacy and effectiveness of MC.
In this paper, we first review and discuss the efficacy and effectiveness of MC on HIV, in particular the incremental benefit of MC on HIV infection due to its indirect protection against cofactor STIs in the context of the three aforementioned randomised trials (10) (11) (12) .
In addition, we present new results on the incremental benefit of MC at the populationlevel due to its efficacy against other STIs.
Methods
The population-level impact of MC on HIV prevalence was assessed using a previously validated stochastic compartmental model which simulates transmission of HIV and one STI in the heterosexual population in the Kisumu district of Kenya (12, 14) . The modelled population was stratified into six sexual activity classes with specific rates of sexual partner acquisition. In absence of specific data, the mixing between activity classes was assumed to be proportionate. The STI was modelled with two compartments representing Upon commencement of the circumcision intervention, a fixed number of susceptible men were recruited from the uncircumcised to the circumcised susceptible compartment.
The model structure, the equations and the Monte-Carlo simulation process are fully described in Supplement material.
High(scenario A) and low(scenario B) STI prevalence scenarios were modelled. The distribution by sexual activity classes and rates of sexual partner acquisition for scenario B were selected to agree with infection rates in the Kisumu UNIM male circumcision trial population (12, (14) (15) (16) (17) and the 2003 Kenyan Demographic and Health Survey (15) corresponding to years 15-17 of the simulated epidemic. Remaining parameters for HIV (14, (18) (19) (20) (21) (22) (23) and STI(27-29) transmission probabilities, duration of the different HIV states (14,18-24-26) and duration of STI infection(27-29) were based on published studies( Table 2 ).
The presence of STI in the HIV-infected sexual partner was assumed to increase HIV Table 2 . In both scenarios, the male HIV prevalence was 28% at year 15 and declined as the epidemic progressed due to a strong dependence on STI prevalence which declined due to AIDS differential mortality. In scenario A, the overall STI and HIV prevalence, and HIV incidence averaged 22.3%, 29.8%, and 5. 
Theoretical context
Individual-level effect of MC: Efficacy vs Effectiveness
In the clinical trial literature, "efficacy" is typically defined as the individual-level clinical/biological benefit of the intervention used under ideal conditions(e.g. with 100%
compliance and adherence) -reflecting the maximal effect it can have. Individual-level "effectiveness", often termed 'real world' effectiveness, (not to be confounded with the population-level effectiveness) refers to the effect of the intervention achieved under more realistic conditions of use(e.g., imperfect adherence) and relates more closely to the potential benefit of the intervention to individuals when widely used in practice(33-34). In RCTs, where HIV negative individuals are randomized and follow-up, it is only possible to estimate a reduction in acquisition to HIV(E s HIV ) and STIs(E s STI )
independently(34).
Because cofactors STI were on the causal pathway to HIV infection, the primary outcome of the three circumcision trials was the overall effectiveness of MC on HIV acquisition, rather than the independent efficacies against HIV and STIs(11). Thus, the overall effectiveness(i.e. the overall reduction in HIV incidence) measured in the trials could have been the result of a combination of direct protection(efficacies) against HIV However, in a very recent clinical trial in Rakai, higher(but not statistically significant)
HIV incidence was observed among the wives of circumcised HIV positive men, which was attributed to premature resumption of sexual activity following the surgical procedure, rather than behavioural disinhibition(37).The protective effect of MC against
STIs is more uncertain(37-45). A meta-analysis suggested a 33% and 12% reduction in the risk of syphilis and HSV-2 among circumcised men, respectively (38) . The estimates across different observational studies varied between -10% to 88% for chancroid.
Evidence on the protective effect against gonorrhoea is unclear and mostly based on early studies (9, 39, (41) (42) (43) (44) . One study suggested a reduced rate of Chlamydia transmission to their female partners by circumcised compared to uncircumcised men (45 11, 38, 40) . We assumed that male-to-female HIV transmission was unchanged by circumcision status (Table 2) .
Results
Insights from previous clinical trial simulations
The protective role of MC against cofactor STI on the risk of HIV infection at the individual-level was assessed in Desai et al(14 study, where a small fraction of men were follow-up for two years in the simulated UNIM MC trial in Kisumu( or when the RR S was increased to six-fold respectively. As these assumptions, especially the 100% efficacy against the STI appeared unrealistically high, the authors concluded that the effectiveness above 50%, as observed in the field RCT, could not have been due solely to the protection against cofactor STI. MC needed to strongly protect directly against HIV (14) . In addition, under the STI conditions, MC needed to have an HIV efficacy of at least 40% and 50% to generate the observed overall effectiveness of 50% or 60% against HIV, respectively, even if the efficacy against STI was as high as 60% (14) .
This also meant that if the MC efficacy against HIV was 40%, not more than 20% of the HIV infections prevented in the circumcised arm of the trial could be attributable to the efficacy against the STI(rather than efficacy against HIV). This proportion decreased as the efficacy against HIV increased( Figure 1A) .
Insight from the three MC circumcision trials
The effect of circumcision on STI incidence was not reported in the South African trial(10). The baseline STI prevalence only was reported in the Kenyan trial. Gray et al(11) reported a baseline prevalence of 7% and a 47%(95% CI: 36%-57%) reduction in self-reported GUD in the circumcised arm during part of the trial (Table 1) . In subgroup analysis, an effectiveness of 40%(95% CI: 8%, 66%) against HIV was reported in the GUD negative group compared to an effectiveness of 51%(95% CI: 16%, 72%) for the whole cohort. In line with the meta-analysis results for high-risk individuals(6), the Rakai sub-group analyses reported an effectiveness of 71%(95% CI -29%, 97%) and 70%(95% CI: 15%, 91%) in men reporting more than 2 partners and with self-reported GUD, respectively. Based on our simulation results, the difference between an effectiveness of 70% and an effectiveness of 50%-60% among high-risk individuals compared to general population, respectively, could partly be explained by the additional protection of MC against STIs if the STI prevalence(>>20%) or the recurrence of ulcers among high-risk individuals is high. In addition, under the UNIM trial conditions, MC efficacy against HIV is predicted to be at least 40%-50% given that the observed individual-level MC effectiveness in the three trials was 50%-60%.
Insights from new simulation results: Population-level and long term impact
Because the trials were of short duration and only captured the reduction in susceptibility Our results support previous modelling studies suggesting that MC has the potential to help curb the HIV epidemic in the long term, in population where MC prevalence is low and in absence of associated sexual disinhibition (46) (47) (48) (49) (50) (51) . If enough men are circumcised, females will benefit from long-term herd immunity effects. In our model, men were circumcised in a short window period. In practice such high coverage would be reached over a longer term period. It is therefore important to determine who should be circumcised first(e.g., younger and more sexually active men) in order to scale-up circumcision programme to achieve maximum impact very rapidly (51) . The populationlevel impact of MC would even be larger, especially for females if it also reduced the infectiousness of HIV positive circumcised men. However, it could also have detrimental effects if men were more infectious to their female partners immediately after the procedure(37,46). This has obvious implications for the roll-out of mass circumcision.
In the long term, our analysis suggested that the incremental population-level impact of MC on HIV due to a reduction in the acquisition of STIs(E s STI ) among male is also likely to be small. Although we only modelled one generic STI, our conclusions remained valid under extreme assumptions of high MC efficacy against STI (higher than what has been observed), strong STI and HIV association, and very high STI prevalence (Figure 2 ). The incremental benefit of E s STI was marginally better for women than men simply because their protection was mediated by herd immunity effects through the rapid decline in STI prevalence among men. Based on current knowledge, we assumed that MC reduced acquisition of new STIs. However, if MC also reduced the frequency or duration of ulcers during the course of infection (11, 40) , this may provide additional incremental benefits. Our results do not demonstrate that MC does not protect against STIs. They only predict that the incremental impact of MC against HIV due to a reduction in males' for a GU problem in the 12 months prior to the visit at month 12 was 4.7% in the intervention group compared to the control group(7.2%).
Self-reported STI: GUD: 47%(36%-57%) Genital discharge: 16%(-11%, 37%) Dysuria: 3%(-21% 
